Document is current
Any future updates will be listed below
-
Authors
Li, Andrew T.
Vakharia, Kavita
Lo, Serigne N.
Varey, Alexander H. R.
Carlino, Matteo S.
Saw, Robyn P. M.
Shannon, Kerwin F.
Howle, Julie R.
Pennington, Thomas E.
Stretch, Jonathan R.
Nieweg, Omgo E.
Spillane, Andrew J.
Long, Georgina V.
Menzies, Alexander M.
Scolyer, Richard A.
Thompson, John F.
Ch’ng, Sydney
- License Information
-
More Information
Article History
Received: 15 April 2021
Accepted: 24 June 2021
First Online: 4 August 2021
Disclosure
: Matteo S. Carlino has served on advisory boards for Bristol-Myers Squibb, MSD, Amgen, Novartis, Pierre Fabre, Roche, Sanofi, Merck, Ideaya, Regeneron, Nektar, Eisai, Oncosec, and Qbiotics and has received honoraria from Bristol-Myers Squibb, MSD, and Novartis. Robyn P. M. Saw has received honoraria for advisory board participation from MSD, Novartis, and Qbiotics as well as speaking honoraria from BMS. Andrew J. Spillane has received honoraria for advisory board participation from Qbiotis and speaker honoraria from Stryker. Georgina V. Long is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, Nektar, Pierre Fabre, QBiotics Group Limited, and Regeneron Pharmaceuticals Inc. Richard A. Scolyer has received fees for professional services from Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. Alexander M. Menzies has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics. John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel support from GSK and Provectus Inc.
